News

Prescient Therapeutics delivers positive immune response test results

July 7, 2021

Prescient Therapeutics delivers positive immune response test results

Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing demonstrated the company’s OmniCAR binding systems for next-generation CAR-T therapies are unlikely to trigger adverse reactions.

Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing demonstrated the company’s OmniCAR binding systems for next-generation CAR-T therapies are unlikely to trigger adverse reactions.

The ‘in silico’ tests – referring to tests conducted through computer modelling – found Prescient’s ‘SpyTag’ and ‘SpyCatcher’ binding systems both have very low ‘immunogenicity’.

Immunogenicity testing measures the response human immune systems have to drugs and treatments, with lower immunogenicity readings less likely to produce unwanted or even dangerous immune responses from patients.

SpyTag and SpyCatcher both produced immunogenicity readings lower than “a panel of humanised therapeutic antibodies already approved for human use”, the company said in a statement.

Steven Yatomi-Clarke, the company’s CEO and Managing Director, described the results as an “incremental but important milestone” in Prescient’s work to develop the next generation of CAR-T cancer therapies.

CAR-T therapies use a patient’s own immune cells (known as T-Cells) to fight cancer by genetically modifying the cells to identify and attack tumours, however the current generation treatments have issues with safety and control and can only attack one cancer target.

Prescient’s next-generation OmniCAR platform – which incorporates SpyTag and SpyCatcher – aims to overcome these challenges by allowing greater control, the ability to redirect modified T-Cells, and improved safety outcomes.

Mr Yatomi-Clarke said the latest immunogenicity results de-risk the entire OmniCAR platform.

“In short, it gives us confidence that if these therapies are ultimately delivered to patients, that their immune system will not impair the therapy itself,” he said.

“This is essential not only for Prescient’s three in-house OmniCAR programs, but also for potential collaborators, who consider immunogenicity very stringently.”

The test results follow successful manufacturing and delivery of “critical” OmniCAR components, and place the company “on schedule” to deliver further milestones in line with Prescient’s development plan.

To stay up-to-date on Prescient’s news and announcements, register your details on the Investor Centre.

 

Reach Markets have been engaged by PTX to help manage their investor communications

Sources:

 


General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.

Lombok Property Group

Ideal opportunity for investors in a growing property and tourism market

Leave a comment